Dr. Robert Huizinga reports

KANE BIOTECH ANNOUNCES PUBLICATION IN FRONTIERS IN ANTIBIOTICS HIGHLIGHTING ADVANCEMENTS IN TREATING ANTIBIOTIC TOLERANT BIOFILMS

Frontiers in Antibiotics has published a peer-reviewed article authored by researchers from Kane Biotech Inc. and the University of Manitoba, detailing important scientific advancements in the fight against antibiotic-tolerant biofilms.

Key messages of the article as it relates to Kane's revyve wound gel include:

• revyve antimicrobial wound gel demonstrated strong activity against antibiotic-tolerant biofilms, a major barrier in the treatment of chronic wounds.
• In both in vitro and ex vivo models, revyve eliminated mature staphylococcus aureus and pseudomonas aeruginosa biofilms, even after they had developed high levels of antibiotic tolerance.
• Following antibiotic pretreatment, which generated highly antibiotic-tolerant cells, revyve achieved large log-scale reductions in surviving populations, often driving bacterial counts below detectable limits within 24 to 72 hours.
• In summary, these results show that revyve effectively inactivates stubborn biofilms, supporting its potential as a valuable advanced-wound-care tool for improving healing outcomes in chronic, biofilm-laden wounds.

United States Food and Drug Administration 510(k) cleared and Health Canada-approved revyve antimicrobial wound gel

The forthcoming publication, titled "Efficacy of a Novel Thermo-Reversible Wound Gel Against Antibiotic Tolerant Biofilm," underscores Kane's growing leadership in biofilm-targeted therapeutics and adds to the expanding body of evidence supporting innovative approaches to wound and burn management. First-authored by Dr. Jeyachchandran Visvalingam, internal R&D leader, and including contributions from Dr. Sarvesh Logsetty, renowned burn and trauma surgeon at the Max Rady College of Medicine, University of Manitoba, the study contributes meaningful insights into how thermo-reversible antibiofilm and antimicrobial technologies can address one of the most persistent challenges in modern wound care.

Frontiers in Antibiotics is a peer-reviewed, open-access journal that focuses on antibiotic development, resistance and clinical applications.

"Having our research published in Frontiers in Antibiotics as an open-access article is an important milestone for Kane Biotech as we continue to commercialize revyve across wound and burn care markets," said Dr. Robert Huizinga, interim chief executive officer of Kane Biotech. "This peer-reviewed journal is recognized for its rigorous scientific standards and transparent review process. This publication reinforces the strength of our technology and supports our mission to bring advanced, biofilm-targeted solutions to patients."

About Kane Biotech Inc.

Kane Biotech is commercializing and developing novel wound care treatments that disrupt biofilms and transform healing outcomes. Biofilms are one of the main contributors to antibiotic resistance in wounds, resulting in serious clinical outcomes and significant cost. revyve addresses both biofilms and wound bacteria. revyve antimicrobial wound gel, revyve antimicrobial wound gel spray, and revyve antimicrobial skin and wound cleanser are all U.S. FDA 510(k) cleared. revyve antimicrobial wound gel and revyve antimicrobial wound gel spray are also Health Canada approved.

We seek Safe Harbor.